Working Paper |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
"Do non-R&D intensive industries benefit of spillovers from public research? The case of the Agro-food industry |
0 |
0 |
0 |
15 |
1 |
1 |
2 |
56 |
Aligning Strategies for Growth and Talent Management in Creative Professional Service Firms |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
85 |
Biotech Innovation in Europe's Food and Drink Processing Industry: Promise, Barriers and Exploitation |
0 |
0 |
0 |
20 |
1 |
1 |
1 |
111 |
Business models: A challenging agenda |
0 |
0 |
1 |
48 |
0 |
4 |
6 |
140 |
Cléopâtre et son goûteur |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
172 |
Community as a locus of innovation: co-innovation with users in the creative industries |
0 |
0 |
0 |
46 |
0 |
0 |
1 |
110 |
Competing business models in the french biotech industry |
0 |
0 |
0 |
21 |
0 |
2 |
2 |
93 |
Creation and growth of high-tech SMEs: the role of the local environment |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
Creation of biotech SMEs in France |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
47 |
Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
36 |
Disassembly and reassembly on digital technology and creative industries |
0 |
0 |
1 |
42 |
0 |
0 |
3 |
68 |
Diversification and hybridisation in firm knowledge bases in nanotechnologies |
0 |
0 |
0 |
89 |
0 |
1 |
2 |
381 |
Diversification and hybridization in firm knowledge bases in nanotechnologies |
0 |
0 |
0 |
10 |
1 |
2 |
3 |
105 |
Do Science and Money Go Together? The Case of the French Biotech Industry |
0 |
0 |
1 |
16 |
1 |
1 |
4 |
85 |
Editor's Introduction: Scientific and Technical Human Capital |
0 |
0 |
3 |
28 |
0 |
1 |
12 |
99 |
Emergence des nanotechnologies: Vers un nouveau "modèle industriel "? |
0 |
0 |
0 |
38 |
0 |
0 |
0 |
182 |
Entre discrimination et autocensure. Les carrières des femmes dans l'enseignement supérieur et la recherche |
0 |
0 |
0 |
84 |
0 |
1 |
2 |
382 |
Explorer pour innover, répliquer pour séduire |
0 |
0 |
0 |
5 |
1 |
1 |
1 |
47 |
French Biotech Start-Ups and Biotech Clusters in France. The Importance of Geographic Proximity |
0 |
0 |
0 |
23 |
0 |
0 |
2 |
125 |
From Business model to Business model portfolio in the european biopharmaceutical industry |
0 |
0 |
0 |
56 |
1 |
1 |
2 |
140 |
From individual scientific visibility to collective competencies: the example of an academic department in social science |
0 |
0 |
0 |
6 |
1 |
1 |
4 |
111 |
From sectoral to horizontal public policies: the evolution of support for biotechnology in Europe, 1994-2001 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
Global Contests in the Production of Business Knowledge |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
49 |
How do Academics adopt new practices during a reform ? The Evolution of doctoral education in France 1992-2009 |
0 |
0 |
0 |
14 |
0 |
0 |
1 |
39 |
How long is co-operation in genomics sustainable? |
0 |
0 |
0 |
2 |
1 |
1 |
1 |
20 |
Idiosyncratic distances: Impact of mobile technology practices on role segmentation and integration |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
Industry Life Cycle, Knowledge Generation and Technological Networks |
0 |
1 |
1 |
20 |
0 |
1 |
1 |
82 |
Innovation et création dans le jeu vidéo: comment concilier exploration exploration et exploitation |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
Institutional change and professional practices: The case of French doctoral education |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
48 |
Is the Creation and Development of Biotech SMEs Localised? Conclusions Drawn from the French Case |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
34 |
L'influence de l'environnement régional sur la création et la croissance des PME de biotechnologie |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
43 |
LARGE PLAYERS IN THE NANOGAME: DEDICATED NANOTECH SUBSIDIARIES OR DISTRIBUTED NANOTECH CAPABILITIES? |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
74 |
La confiance: un mode de coordination dont l'utilisation dépend de ses conditions de production |
0 |
0 |
0 |
43 |
0 |
0 |
3 |
300 |
Learning in MNCs: How subsidiary managers do (and do not) create global solutions |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
56 |
Orchestrating networks in the biopharmaceutical industry: small hub firms can do it |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
40 |
PIS AS BOUNDARY SPANNERS, SCIENCE AND MARKET SHAPERS |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
41 |
PME de biotechnologie: Plusieurs Business models en concurrence |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
148 |
Profile of public laboratories, industrial partnerships and organisation of R & D: the dynamics of industrial relationships in a large research organisation |
0 |
1 |
1 |
15 |
0 |
1 |
2 |
87 |
Project Management: Learning by violating principles |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
16 |
Project management learning by violating principales |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
14 |
Project management: learning by breaking the rules |
0 |
0 |
2 |
231 |
0 |
0 |
4 |
638 |
REJUVENATING NANOCLUSTERS WITH 'SLEEPING ANCHORS': PRE-ADAPTATION AND LIFE CYCLE |
0 |
0 |
1 |
12 |
0 |
0 |
1 |
80 |
Recherche ou temps perdu ? Vers une intégration des tâches administratives au métier d'enseignant chercheur |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
27 |
Reputational spillovers: evidence from french architecture |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
31 |
Start-up mid and long term strategic management using a business model portfolio |
0 |
0 |
0 |
6 |
1 |
1 |
1 |
34 |
Stimulating Knowledge Search Routines and Architecture Competences: The Role of Organizational Context and Middle Management |
0 |
0 |
1 |
2 |
1 |
1 |
3 |
34 |
Subsidiary managers’ knowledge mobilizations: Unpacking emergent knowledge flows |
0 |
0 |
0 |
1 |
1 |
3 |
11 |
47 |
Surfing on institutions: When temporary actors in organizational fields respond to institutional pressures |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
17 |
THE DETERMINANTS OF THE SCIENCE-BASED CLUSTER GROWTH: THE CASE OF NANOTECHNOLOGIES |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
66 |
THE FUTURE OF NANOTECHNOLOGIES |
0 |
1 |
1 |
20 |
1 |
2 |
2 |
84 |
THE ROLE OF PRACTICES IN INSTITUTIONAL CHANGE THE EVOLUTION OF DOCTORAL PROGRAMS IN FRANCE 1990 – 2008 |
0 |
0 |
0 |
38 |
0 |
0 |
0 |
53 |
Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry |
0 |
1 |
1 |
67 |
0 |
1 |
2 |
315 |
Technological agglomeration and the emergence of clusters and networks in nanotechnology |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
107 |
Technological agglomeration and the emergence of clusters and networks in nanotechnology |
0 |
0 |
0 |
213 |
0 |
1 |
2 |
670 |
Technological competition, strategies of the firms and the choice of the first users: the case of road guidance technologies |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
21 |
The Carrers of Social Science Doctoral Graduates in France: the Influence of How the Research was Carried Out |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
101 |
The Dynamics of Innovation Networks |
0 |
0 |
0 |
239 |
0 |
0 |
0 |
404 |
The Evolution of the French Public Policy to Promote Biotech Innovation: The Case of Genomics |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
38 |
The Simultaneous Shaping of Organization and Technology Within Co-operative Agreements |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
58 |
The future of drug discovery and development: Shifting emphasis towards personalized medicine |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
27 |
The inhibiting factors that principal investigators experience in leading publicly funded research projects |
0 |
0 |
0 |
7 |
1 |
2 |
5 |
38 |
The role of regional institutional entrepreneurs in the emergence of clusters in nanotechnologies |
0 |
0 |
0 |
297 |
1 |
1 |
4 |
880 |
Turning scientific and technological human capital into economic capital: the experience of biotech start-ups in France |
0 |
0 |
0 |
17 |
1 |
2 |
2 |
99 |
Underpinning Strategic Behaviours and Posture of Principal Investigators in Transition/Uncertain Environments |
0 |
0 |
0 |
3 |
0 |
0 |
1 |
29 |
Understanding the emergence and deployment of “nano” S&T |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
112 |
University Technology Transfer offices: the search for identity to build legimacy |
0 |
0 |
0 |
22 |
2 |
2 |
4 |
146 |
WHEN CELEBRITY DESTROYS ARTISTIC REPUTATION: THE CASE OF FRENCH ARCHITECTS |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
70 |
When technological discontinuities and disruptive business models challenge dominant industry logics: insights from the drugs industry |
0 |
0 |
0 |
51 |
1 |
2 |
3 |
130 |
Total Working Papers |
0 |
4 |
14 |
2,101 |
20 |
43 |
120 |
8,075 |